The pace of artificial intelligence (AI) adoption in personalised medicine is unsettling for great parts of the public. A new survey reflects the worried state of mind in the UK.
Using genomic sequencing data, researchers have created personalised simulations of individual patients that can quantify the impact of genetic mutations on cancer cell behaviour.
Using advanced technology from the automotive and manufacturing industries, researchers are driving medical advancement to create ‘personalised’ hip replacements.
Researchers have developed a cutting-edge method for fabrication of customised pharmaceutical tablets with tailored drug release profiles, ensuring more precise and effective treatment options.
Generalist Medical Artificial Intelligence (GMAI) models pose a significant challenge to current regulatory frameworks. Experts discuss how regulation of these models could work in the future.
Researchers discovered three distinct immunological endophenotypes of multiple sclerosis, defined by specific blood immune signatures. This opens new avenues for personalized treatment strategies.
In a breakthrough for personalised oncology, scientists have developed and demonstrated a novel platform that can significantly reduce the time needed to determine the efficacy of anti-cancer drugs.
AI technology holds promise for personalised cancer therapies. However, rigid and slow approval requirements impede its introduction, say experts – and point out how this might be changed.
An 'encyclopaedia' of protein alterations in soft tissue sarcomas could open the door to a new era of understanding and treatment for this group of rare cancers.
University of Ottawa scientists have introduced a metal-free MRI dye capable of mapping kidney function with unprecedented accuracy — a promising technique for more personalized care.
AI, robotics, climate change and more: Swedish researchers outline emerging technologies and trends that may define what the healthcare industry looks like in the next 50 years.
Genomic sequencing panels as part of personalised cancer treatment have been found to only benefit one in 20 patients they are currently used for, according to a study by CNIO.
Unanswered questions are hampering clinicians in their efforts to get the best out of a precision medicine approach for their patients. Speaking at the Genomics and Precision Medicine Expo in London at the end of May, cancer educator Dr Elaine Vickers said the benefits of being matched to an investigational drug remain questionable for most people with advanced cancer.
The accuracy of prostate-specific antigen (PSA) screening can be improved by including genetic factors that cause changes in PSA levels not associated with cancer, according to a multi-center study.
Researchers from the Organoid group (Hubrecht Institute) and UMC Utrecht have developed a biobank with organoids derived from patients with head and neck cancer (HNC).
Radiation exposure in diagnostic and interventional radiology is steadily being reduced, but some important parameters have hardly been taken into account so far, says Dr Kerstin Jungnickel. The medical physics expert explains how patient-specific protocols can improve radiation protection and outlined new findings on the radiosensitivity of certain body regions and their impact.
60 percent of all administered drugs do not have the desired therapeutic effect. Even worse: in Germany alone about 60,000 deaths per year are caused by medication. With these shocking statistics Professor Dr Christian Franken started his presentation on “Pills from the 3D printer” at last year’s Medica in Düsseldorf. He hopes that his vision of personalized medication based on 2D and 3D…
According to an international group of researchers led by Leiden University Medical Center (LUMC), patients experience 30% fewer serious side effects when medication doses are tailored to their DNA.
Philips is an active participant in the new European Federation for Cancer Images consortium (EUCAIM) – a project launched in the run-up to World Cancer Day 2023.
